Juvenile localized scleroderma: clinical picture, diagnosis, therapeutic update (literature review and own observations)

L.F. Bogmat, V.V. Nikonova


Among rheumatic diseases in children, a special place belongs to juvenile localized scleroderma, which is highlighted as a separate form in the structure of scleroderma diseases and is characterized by: the onset of the disease up to 16 years, skin lesions, often focal or linear (hemiforma), a tendency to form contractures and the development of limbs abnormalities. This form of the disease is characterized by damage to the skin mainly involving the surrounding muscles. The cause of juvenile localized scleroderma is unclear. Three main components underlie the development of the disease: damage to the vascular bed, activation of the immune system with a violation of its regulation and release of cytokines, as well as altered collagen synthesis with proliferation of fibroblasts and the subsequent development of fibrosis. Several forms of juvenile localized scleroderma have been identified, differing in clinical manifestations and depth of lesion of subjacent tissues, and among the skin manifestations, five subtypes are distinguished: plaque, generalized, linear, pansclerotic, and mixed. Diagnosis is based on an analysis of the history and typical clinical picture of the disease. Specific laboratory tests to confirm the disease has not been developed. Modern treatment principles for juvenile localized scleroderma involve the use of different groups of drugs, including methotrexate, corticosteroids, tacrolimus, cyclosporine, imatinibum, mycophenolate mofetil, retinoids, PUVA therapy (Psoralen + UltraViolet A), use of slow calcium channel antagonists (nifedipinum group), bosentan. The studies currently being conducted in the world on the standardization of basic therapy of juvenile localized scleroderma are likely to reveal the optimal variant and duration of treatment for each form of the disease and improve the prognosis of the disease. The article also presents the results of own clinical observations.


review; rheumatic diseases; juvenile localized scleroderma; children


Athreya BH. Juvenile scleroderma. Curr Opin Rheumatol. 2002 Sep;14(5):553-61. doi: 10.1097/00002281-200209000-00013.

Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011 Feb;64(2):217-28; quiz 229-30. doi: 10.1016/j.jaad.2010.05.045.

Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013 Jul-Aug;31(4):432-437. doi: 10.1016/j.clindermatol.2013.01.010. 

Zulian F, Athrea B, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006 May;45(5):614-20. doi: 10.1093/rheumatology/kei251.

Shostak NA, Dvornikov AS, Klimenko AA, Kondrashov AA, Skripkina PA, Gaidina TA. Localized (focal) scleroderma in the general medical practice. Lečebnoe delo. 2015;4:45-53.

Osminina M.K., Geppe N.A. Classification issues, clinical presentation and basic therapy of juvenile scleroderma. Rheumatology Science and Practice. 2015;53(2):214-219. doi: 10.14412/1995-4484-2015-214-219. (In Russian).

Weibel L. Localized scleroderma (morphea) in childhood. Hautarzt. 2012 Feb;63(2):89-96. doi: 10.1007/s00105-011-2199-5.

Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995 Nov;70(11):1068-76.  doi: 10.4065/70.11.1068.

Fett NM. Morphea (localized scleroderma). JAMA Dermatol. 2013 Sep;149(9):1124. doi: 10.1001/jamadermatol.2013.5079.

Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Irelands. Arthritis Care Res (Hoboken). 2010 Feb;62(2):213-8. doi: 10.1002/acr.20070.

Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol. 2017 Aug;18(4):491-512. doi: 10.1007/s40257-017-0269-x.

Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update An Bras Dermatol. 2015 Jan-Feb;90(1):62-73. doi: 10.1590/abd1806-4841.20152890.

Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr. 2013 Oct;104(8):654-66. doi: 10.1016/j.adengl.2012.10.012.

Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008 Sep;20(5):601-7. doi: 10.1097/BOR.0b013e328309a5eb.

Atzeni F, Bardoni A, Cutolo M, et al. Localized and systemic forms of scleroderma in adults and children. Clin Exp Rheumatol. 2006 Jan-Feb;24(1 Suppl 40):S36-45.

Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016 Feb;14(2):199-216. doi: 10.1111/ddg.12724.

Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009 Dec;36(12):2819-29. doi: 10.3899/jrheum.081284. 

Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):220-5.

Zulian F, Martini G, Vallongo C, et al. Methotrexate in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011 Jul;63(7):1998-2006. doi: 10.1002/art.30264.

van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observation trial. Br J Rheumatol. 1996 Apr;35(4):364-72.

Teske NM, Jacobe HT. Phototherapy for sclerosing skin conditions. Clin Dermatol. 2016 Sep-Oct;34(5):614-22. doi: 10.1016/j.clindermatol.2016.05.012.

Buense R, Duarte IA, Bouer M. Localized scleroderma: assessment of the therapeutic response to phototherapy. An Bras Dermatol. 2012 Jan-Feb;87(1):63-9. doi: 10.1590/s0365-05962012000100007.

Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. Randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006 Mar;54(3):440-7. doi: 10.1016/j.jaad.2005.11.1063.

Hanson AH, Fivenson DP, Schapiro B. Linear scleroderma in an adolescent woman treated with methotrexate and excimer laser. Dermatol Ther. 2014 Jul-Aug;27(4):203-5. doi: 10.1111/dth.12117.

Brady SM, Shapiro L, Mousa SA. Current and future direction in the management of scleroderma. Arch Dermatol Res. 2016 Sep;308(7):461-71. doi: 10.1007/s00403-016-1647-6.

Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: A road map toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85. doi: 10.1002/acr.21687.

Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011 Nov;65(5):925-41. doi: 10.1016/j.jaad.2010.09.006.

Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005 Jul;141(7):847-52. doi: 10.1001/archderm.141.7.847.

Pérez Crespo M, Betlloch Mas I, Mataix Díaz J, Lucas Costa A, Ballester Nortes I. Rapid response to cyclosporine and maintenance with methotrexate in linear scleroderma in a young girl. Pediatr Dermatol. 2009 Jan-Feb;26(1):118-20. doi: 10.1111/j.1525-1470.2008.00848.x.

Rattanakaemakorn P, Jorizzo JL. The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype). J Dermatolog Treat. 2018 Mar;29(2):197-199. doi: 10.1080/09546634.2017.1341615.

Copyright (c) 2020 L.F. Bogmat, V.V. Nikonova

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта